^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Small Cell Lung Cancer

    Related cancers:
    3d
    Management of Pulmonary Large-Cell Neuroendocrine Carcinoma (LCNEC): An Updated Review. (PubMed, Clin Lung Cancer)
    For unresectable, locally advanced disease, concurrent chemoradiation with etoposide-cisplatin followed by consolidation durvalumab is recommended, although the optimal dose-fractionation and the duration of consolidation immunotherapy remain to be investigated. Among the most promising emerging treatment strategies are DLL3-targeting therapies, buoyed by the recent success of tarlatamab in SCLC. The evolving role of molecular profiling in prognostication and treatment decision-making is also examined.
    Review • Journal
    |
    DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    cisplatin • Imfinzi (durvalumab) • etoposide IV • Imdelltra (tarlatamab-dlle)
    3d
    Structural and functional insights into CD3 bispecific antibodies targeting DLL3 in cancer immunotherapy. (PubMed, Med Oncol)
    This study systematically characterized three clinical-stage CD3×DLL3 BsAbs, Tarlatamab (AMG757), BI764532 and HPN328, via structural modeling, T-cell activation assays, cytokine profiling, and tumor cytotoxicity tests. BI764532 demonstrated a balanceed efficacy (ORR 18% in SCLC), while Tarlatamab achieved an ORR range of 13-40% across clinical trials. IS distance and epitope binding are strongly correlated with efficacy and safety of DLL3-targeted BsAbs, providing a critical framework for optimizing T-cell engager design in cancer immunotherapy.
    Journal
    |
    DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    obrixtamig (BI 764532) • Imdelltra (tarlatamab-dlle) • gocatamig (MK-6070)
    3d
    Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV (clinicaltrials.gov)
    P1, N=8, Active, not recruiting, National Cancer Institute (NCI) | N=18 --> 8 | Trial completion date: Nov 2025 --> Feb 2027
    Enrollment change • Trial completion date
    |
    CD4 (CD4 Molecule)
    |
    Opdivo (nivolumab) • Cabometyx (cabozantinib tablet) • Cometriq (cabozantinib capsule) • ABP 206 (nivolumab biosimilar)
    3d
    RAISE: Niraparib Added to Anti-PD-L1 Antibody Maintenance in SLFN11-positive, Extensive-disease SCLC (clinicaltrials.gov)
    P2, N=44, Recruiting, ETOP IBCSG Partners Foundation | Trial completion date: Jun 2026 --> Jun 2027 | Trial primary completion date: Dec 2025 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    SLFN11 (Schlafen Family Member 11)
    |
    Zejula (niraparib)
    3d
    IMFINZI-subQ: A Phase I Dose Escalation and Dose Expansion Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Durvalumab (clinicaltrials.gov)
    P1, N=40, Not yet recruiting, AstraZeneca
    New P1 trial
    |
    Imfinzi (durvalumab) • Imjudo (tremelimumab-actl)
    3d
    DAREON-5: DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers (clinicaltrials.gov)
    P2, N=174, Recruiting, Boehringer Ingelheim | Trial completion date: Jul 2027 --> Feb 2028 | Trial primary completion date: Jan 2027 --> Sep 2027
    Trial completion date • Trial primary completion date
    |
    PD-L1 (Programmed death ligand 1) • DLL3 (Delta Like Canonical Notch Ligand 3)
    |
    obrixtamig (BI 764532)
    3d
    SNB-101-101: SNB-101 for Treatment of Extensive Stage Small Cell Lung Cancer (clinicaltrials.gov)
    P1/2, N=55, Not yet recruiting, SN BioScience
    New P1/2 trial
    |
    SNB-101
    4d
    Safety and Efficacy Analysis of Oral Etoposide Combined With Anlotinib and Envafolimab in First-line Treatment of Elderly Patients With Small Cell Lung Cancer/ Open-label, Single-arm, Exploratory Phase II Clinical Study (clinicaltrials.gov)
    P2, N=30, Active, not recruiting, Tianjin Medical University Cancer Institute and Hospital | Trial completion date: Dec 2025 --> May 2026
    Trial completion date
    |
    Focus V (anlotinib) • etoposide oral • Enweida (envafolimab)
    4d
    [Retracted] MicroRNA‑4500 suppresses tumor progression in non‑small cell lung cancer by regulating STAT3. (PubMed, Mol Med Rep)
    The Editor apologizes to the readership for any inconvenience caused. [Molecular Medicine Reports 20: 4973‑4983, 2019; DOI: 10.3892/mmr.2019.10737].
    Journal
    |
    STAT3 (Signal Transducer And Activator Of Transcription 3)
    4d
    SKB264-ANLO: Sacituzumab Tirumotecan Plus Anlotinib in Previously Treated ES-SCLC (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, China Medical University, China
    New P2 trial
    |
    Focus V (anlotinib) • Jiataile (sacituzumab tirumotecan)
    4d
    Improving Care for Rural Patients With Solid Tumors (clinicaltrials.gov)
    P=N/A, N=320, Recruiting, University of Colorado, Denver | Trial completion date: Jun 2026 --> Jun 2027 | Trial primary completion date: Jan 2026 --> Jan 2027
    Trial completion date • Trial primary completion date
    4d
    An Open-label, First-in-Human, Dose-Escalation and Dose-Expansion Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPR1020 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=210, Recruiting, Shanghai SciBrunch Therapeutics Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open • First-in-human
    |
    HER-2 (Human epidermal growth factor receptor 2) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • HRD (Homologous Recombination Deficiency) • BRCA (Breast cancer early onset) • RAD51C (RAD51 paralog C) • RAD51D (RAD51 paralog D)
    |
    HER-2 negative • HRD • PALB2 mutation • RAD51C mutation • BRCA mutation